Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 3

Conditions

Uterine Cervical Neoplasms 20Papillomavirus Infections 12Uterine Cervical Dysplasia 9Condylomata Acuminata 7Vulvar Neoplasms 4Anus Neoplasms 4Vaginal Neoplasms 3Virus Diseases 1Persistent Infection 1Neoplasms 1Neoplasm Metastasis 1Inflammatory Bowel Diseases 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Crohn Disease 1Colitis, Ulcerative 1Cervical Cancer Screening 1Acquired Immunodeficiency Syndrome 1

Interventions

Radiotherapy 10Cisplatin 9pembrolizumab 6Surveys and Questionnaires 6Methods 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5fludarabine 4Papillomavirus Vaccines 4Early Intervention, Educational 4Cyclophosphamide 4Brachytherapy 4durvalumab 3aldesleukin 3Vaccines, Synthetic 3Vaccines 3Sentinel Lymph Node Biopsy 3Radiosurgery 3Radiation 3Platinum 3Palliative Care 3Paclitaxel 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Drug Therapy 3Carboplatin 3Bleomycin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Papillomavirus Vaccines × Gynecologic × Clear all
NCT06686043 2024-11-13

HPV-VIM

Baylor College of Medicine

Phase 2 Recruiting
85 enrolled
Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Papillomavirus Infections

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 2 Completed
780 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Beijing Health Guard Biotechnology, Inc

Phase 3 Active not recruiting
2,750 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡